Article content continued
As part of the rapid test, individuals will provide a saliva sample into the small handheld tube where the graphene surface inside the unit is designed to bond to the spike protein in the virus, GLC Medical explained in the news release. This binding event changes the electronic characteristics of the graphene and this measurable change is what is used to determine if a person is infected or not.
The device will then show a red or green light in under one minute to indicate if a person is virus free or not. The test is not required to be administered by a medical professional and with training can be administered by anyone, similar to how basic first aid training is done.
With clinical testing ongoing, a start date for the testing program hasn’t been determined. The current plan is to launch the trial this fall with details about the process to be released in the coming weeks.
This trial phase at the airport will be a step forward for GLC Medical in securing certification for its test from Health Canada and other regulatory bodies, including in the United States.
“We are very excited to offer the world a graphene-enhanced rapid solution in COVID-19 virus detection. The opportunity to collaborate with EIA, a world-respected airport authority, to enable travel and to bring families back together is very rewarding for us,” GLC Medical president and CEO Donna Mandau said in the release. “This graphene-enhanced rapid test demonstrates the power of graphene innovation to overcome the challenges of COVID-19. GLC is proud to be a part of EIA’s initiative in setting the global standard in safety and reliability for their travellers.”
GLC Medical, a subsidiary of Graphene Leaders Canada, operates out of the Edmonton Research Park.
View original article here Source